Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STMC-103H in Multi-Sensitized Allergic Subjects
NCT03819881Phase 1Unknown
- Sponsor
- Siolta Therapeutics
- Start
- Oct 2018
- Primary completion
- Nov 2019
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in IgE-mediated allergic disorder comparing STMC-103H with Placebo (2 arms). Primary endpoints: Number of patients with treatment-related adverse events at Day 29, Incidence of abnormal laboratory test results at Day 29 and 3 more. Status: unknown.
02
Drugs
STMC-103H
03
Conditions
IgE-mediated allergic disorder
Beyond the preview
Go deeper on NCT03819881.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03819881.